Recursion Pharmaceuticals
clinical phase studies well tolerated with no dose dependent adverse events in sad and mad mad study placebo further confidence confirming safety | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
94 of 143
Related slides by other companies
Erasca
Investor Presentation
November 2023
clinical activity of in melanoma was reproducible across phase and phase studies a | Erasca
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
Equillium
Investor Presentation
August 2023
milestones | Equillium
ATAI
Investor Presentation
October 2023
trial status first patient dosed in topline data anticipated clinical design phase study | ATAI
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights